IDH1 R132H immunohistochemistry forms a backbone for the differential diagnosis of gliomas. Anti-IDH1 R132H clone H09 (DIA-H09) is an indispensable tool for Glioma diagnosis with high impact on cancer research as documented by nearly 100 scientific publications on CiteAb.
ATRX mutations in gliomas result in the loss of nuclear ATRX expression, which can be diagnosed by IHC analysis. Loss of ATRX expression is close to being mutually exclusive to 1p/19q co-deletion. dianova’s antibody clone AX1 was developed specially for the detection of ATRX in glioma tissue.
The WHO classification 2016 describes the diffuse midline glioma with H3-K27M mutation as a new entity. It is most common in children and adolescents and is localized in midline structures. The clone RM192 enables clear detection of somatic H3 K27M mutations in glioma tissue.
The WHO-classification for CNS Tumors 2016 recommends the analysis of new molecular markers on formalin-fixed tissues together with classical histomorphology. The focus here is on immunohistochemical determination of the IDH1, ATRX and H3-K27M mutation status. Successive integration of IHC procedures reduces the number of molecular tests required for unequivocal diagnosis (Reus et al., 2015).
* Valid until July 1st, 2020. Applies to the combination of ATRX or H3 K27M with one IDH1 R132H antibody DIA-H09 each. When placing placing your order pleace indicate your offer number: 38249
We develop antibodies for the tissue-based detection of immune checkpoint markers
ONCOdianova concentrates on development of new antibody clones for the tissue-based detection of cancer immunology biomarkers. ONCOdianova’s vision is to provide the best antibodies for immunohistochemical analysis of biomarker expression profiles to better understand the complex interaction of immune cells and the tumor cells in patient tissue. ONCOdianova believes that multiplexed IHC-assessment of immune checkpoint targets in tumor tissues is indispensable for cancer research.
Clone 13/45/31 detects N- /C-terminal and internal Histidin-tagged proteins in cells and complex cellular lysates with highest affinity (Biacore 3×10-10M). More than 100 citations demonstrate the outstanding affinity and sensitivity for His-labeled proteins.
Clone RM192: Specific detection of Histone-H3-K27M
Clone RM192 by RevMAb Biosciences allows the specific detection of the Histone H3 K27M mutant in FFPE-tissue samples. The lysin residue (K) at position 27 of the amino acid chain is replaced by a methionine residue (M) in K27M mutant proteins. The monoclonal rabbit antibody does not cross react with wild-type Histone H3.
Western Blot analysis of cell lysates prepared from 293T transfected with a DNA construct encoding wild type (WT) or K27M mutant proteins of Histone H3.3, using anti-Histone H3 K27M rabbit monoclonal antibody, clone RM192.
Image courtesy of Sebastian Brandner MD, Division of Neuropathology and Dept. of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
Prostate Specific Antigen IHC – Performance redefined!
Now available: Best validated anti-PSA antibody worldwide. Clone HAM18 has been tested on 21.000 tissue sections and is optimized for IHC on formalin-fixed paraffin-embedded (FFPE) prostate tissue specimen to be used in brightfield immunohistochemistry but also for fluorescent multiplex immunohistochemistry (mIHC).
Antibody clone HAM18 is absolutely PSA-specific. It stains only prostate epithelium and derived cells. Numerous publications on PSA positive staining of other, non-PSA expressing tumor tissues suggest cross-reactivity of commonly available PSA antibodies. The exceptionally high sensitivity of HAM18 also allows the detection of subtotal to total loss of PSA expression in poorly differentiated tumors of high grades.